Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Over the last 12 months, insiders at Fortress Biotech, Inc. have bought $3.29M and sold $18,900 worth of Fortress Biotech, Inc. stock.
On average, over the past 5 years, insiders at Fortress Biotech, Inc. have bought $2M and sold $123,805 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ROSENWALD LINDSAY A MD (President, CEO & Chairman) — $15.2M. WEISS MICHAEL S (See Remarks) — $499,997.
The last purchase of 10,000 shares for transaction amount of $17,589 was made by ROSENWALD LINDSAY A MD (President, CEO & Chairman) on 2024‑05‑16.
2024-05-20 | Sale | Klein Dov | director | 10,000 0.0504% | $1.89 | $18,900 | -6.12% | |
2024-05-16 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | 10,000 0.0532% | $1.76 | $17,589 | +4.83% | ||
2024-01-05 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | 50,000 0.2671% | $2.38 | $118,770 | -23.05% | ||
2023-11-14 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | 1.57M 1.4832% | $1.70 | $2.66M | +46.92% | ||
2023-11-14 | WEISS MICHAEL S | See Remarks | 147,058 0.1391% | $1.70 | $249,999 | +46.92% | ||
2023-09-26 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | 100,000 0.0734% | $0.28 | $28,330 | -35.51% | ||
2023-08-18 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | 10,000 – | $9.34 | $93,400 | -35.51% | ||
2023-08-17 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | 10,000 – | $11.75 | $117,500 | -35.51% | ||
2023-02-10 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | 2.4M 2.5829% | $0.83 | $2M | -35.51% | ||
2023-02-10 | WEISS MICHAEL S | See Remarks | 1.2M 1.2914% | $0.83 | $999,999 | -35.51% | ||
2023-02-10 | LOBELL J JAY | director | 299,401 0.3229% | $0.83 | $250,000 | -35.51% | ||
2023-02-10 | Jin David | Chief Financial Officer | 35,928 0.0387% | $0.83 | $30,000 | -35.51% | ||
2023-02-10 | Rowinsky Eric K | director | 11,976 0.0129% | $0.83 | $10,000 | -35.51% | ||
2023-02-10 | Lu Lucy | director | 11,976 0.0129% | $0.83 | $10,000 | -35.51% | ||
2022-12-01 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | 100,000 0.1156% | $0.68 | $67,960 | |||
2022-11-30 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | 5,000 0.0048% | $0.56 | $2,800 | |||
2022-11-30 | Jin David | Chief Financial Officer | 5,000 0.0048% | $0.56 | $2,800 | |||
2022-10-21 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | 100,000 0.1146% | $0.69 | $69,500 | |||
2021-12-28 | Sale | Klein Dov | director | 5,000 0.0062% | $2.45 | $12,250 | -59.67% | |
2021-09-21 | Sale | Hunter Robyn | Chief Financial Officer | 28,292 0.0346% | $3.13 | $88,554 | -55.71% |
The Vanguard Group | $958,680.00 | 2.41 | 479,340 | +35.45% | +$250,894.00 | <0.0001 | |
Acadian Asset Management | $582,000.00 | 1.47 | 292,058 | +124.34% | +$322,567.23 | <0.01 | |
Nantahala Capital Management Llc | $556,304.00 | 1.4 | 278,152 | -25.34% | -$188,820.00 | 0.06 | |
Shikiar Asset Management | $446,000.00 | 1.12 | 223,136 | +21.84% | +$79,951.24 | 0.14 | |
National Asset Management Inc | $42.01M | 0.73 | 144,700 | +68.31% | +$17.05M | 0.49 | |
Geode Capital Management | $226,668.00 | 0.57 | 113,317 | +99.86% | +$113,252.99 | <0.0001 | |
Gsa Capital Partners Llp | $215,000.00 | 0.54 | 107,276 | New | +$215,000.00 | 0.02 | |
Ci Private Wealth Llc | $210,652.00 | 0.53 | 105,326 | -2.17% | -$4,664.00 | <0.0001 | |
Envestnet Asset Management Inc | $161,074.00 | 0.4 | 80,537 | +29.14% | +$36,350.00 | <0.0001 | |
BlackRock | $149,878.00 | 0.38 | 74,939 | 0% | +$0 | <0.0001 | |
Wealth Enhancement Advisory Services LLC | $101,872.00 | 0.26 | 50,936 | -46.28% | -$87,760.00 | <0.0001 | |
Northern Trust | $92,404.00 | 0.23 | 46,202 | +361.51% | +$72,382.00 | <0.0001 | |
Myda Advisors Llc | $74,000.00 | 0.19 | 37,000 | New | +$74,000.00 | 0.03 | |
Rsm Us Wealth Management Llc | $72,500.00 | 0.18 | 36,250 | 0% | +$0 | <0.01 | |
Fidelity Investments | $48,442.00 | 0.12 | 24,221 | -0.08% | -$40.00 | <0.0001 | |
Financial Advocates Investment Management | $44,078.00 | 0.11 | 22,039 | New | +$44,078.00 | <0.01 | |
Integrated Wealth Concepts Llc | $40,132.00 | 0.1 | 20,066 | +99.34% | +$20,000.00 | <0.01 | |
State Street | $36,932.00 | 0.09 | 18,466 | 0% | +$0 | <0.0001 | |
Wells Fargo | $34,988.00 | 0.09 | 17,494 | +4,295.48% | +$34,192.00 | <0.0001 | |
Virtu Financial Llc | $31,000.00 | 0.08 | 15,310 | New | +$31,000.00 | <0.01 | |
Goldman Sachs | $23,828.00 | 0.06 | 11,914 | +10.08% | +$2,182.00 | <0.0001 | |
Gladstone Institutional Advisory Llc | $23,000.00 | 0.06 | 11,500 | -4.17% | -$1,000.00 | <0.01 | |
Macquarie Group | $13,000.00 | 0.03 | 6,666 | 0% | +$0 | <0.0001 | |
UBS | $7,550.00 | 0.02 | 3,775 | New | +$7,550.00 | <0.0001 | |
Advisor Group Holdings Inc | $3,838.00 | 0.01 | 1,919 | -95.13% | -$74,992.00 | <0.0001 | |
Morgan Stanley | $4,074.00 | 0.01 | 2,037 | -45.05% | -$3,340.00 | <0.0001 | |
Russell Investments Group Ltd | $4,160.00 | 0.01 | 2,080 | 0% | +$0 | <0.0001 | |
Group One Trading | $1,792.00 | <0.01 | 896 | +2,615.15% | +$1,726.00 | <0.0001 | |
Bank of America | $1,542.00 | <0.01 | 771 | -1.78% | -$28.00 | <0.0001 | |
JPMorgan Chase | $1,344.00 | <0.01 | 672 | -48.11% | -$1,246.00 | <0.0001 | |
Newbridge Financial Services Group Inc | $266.00 | <0.01 | 133 | 0% | +$0 | <0.0001 | |
Qube Research & Technologies | $4.00 | <0.01 | 2 | 0% | +$0 | <0.0001 | |
YHB Investment Advisors, Inc. | $12.00 | <0.01 | 6 | New | +$12.00 | <0.0001 | |
Royal Bank of Canada | $0 | <0.01 | 19 | -99.82% | -$0 | <0.0001 | |
Northwestern Mutual Wealth Management Co | $66.00 | <0.01 | 33 | 0% | +$0 | <0.0001 |